Skip to content
Screener

Arrowhead Research ARWR Investing Cash Flow

Investing Cash Flow at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$23.5M+120%
ALN
Alnylam PharmaceuticalsALNY
-$363.46M-157%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$5.38M-182%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$2.2M-80.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$49M-141%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$25.27M+120%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemSix Months Ended March 31, 2026Six Months Ended March 31, 2025
Purchases of available-for-sale securities(1,061,577)(677,892)
Proceeds from sales of available-for-sale securities23,748
Proceeds from maturities of available-for-sale securities124,518347,402
Net cash used in investing activities(918,024)(343,303)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercises of stock options10,1463,253
Proceeds from issuance of warrants99,99825,000
Proceeds from issuance of convertible notes700,000

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's investing cash flow?
Arrowhead Research (ARWR) reported investing cash flow of -$894.28M in Q1 2026.
How has Arrowhead Research's investing cash flow changed year-over-year?
Arrowhead Research's investing cash flow decreased by 112.8% year-over-year, from -$420.21M to -$894.28M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Arrowhead Research's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude